Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Stéphane Culine (1) , Valentin Harter (2) , Gwenaelle Gravis (3) , Aude Fléchon (4) , Christine Chevreau (5) , Hakim Mahammedi (6) , Brigitte Laguerre (7, 8) , Aline Guillot (9) , Florence Joly (2) , Sophie Abadie-Lacourtoisie (10) , Lionnel Geoffrois (11) , Frederic Di Fiore (12, 13) , Guilhem Roubaud (14) , Philippe Barthélémy (15) , Eric Voog (16) , Sheik Emambux (17) , Camille Serrate (18) , Carolina Saldana (19) , Thierry Nguyen Tan Hon (20) , Yohann Loriot (21) , Jean-Christophe Eymard (22) , Olivier Huillard (23, 24) , Frédéric Rolland (10) , Nadine Houédé (25, 26) , Jean-Philippe Spano (27) , Mounira El Demery , Sabine Vieillot , Tifenn L'Haridon (28) , Werner Hilgers (29) , Yves Allory (30) , Christian Pfister (31)

1 AP-HP - Hopital Saint-Louis [AP-HP]
2 UNICANCER/CRLC - Centre Régional de Lutte contre le Cancer François Baclesse [Caen]
3 IPC - Institut Paoli-Calmettes
4 Département cancer environnement (Centre Léon Bérard - Lyon)
5 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
6 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]
7 Département d'oncologie médicale [Rennes]
8 CRLCC - CRLCC Eugène Marquis
9 Institut de Cancérologie de la Loire Lucien Neuwirth
10 UNICANCER/ICO - Institut de Cancérologie de l'Ouest [Angers/Nantes]
11 UNICANCER/ICL - Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy]
12 CLCC Henri Becquerel - Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen
13 Hôpital Charles Nicolle [Rouen]
14 Institut Bergonié [Bordeaux]
15 CHU Strasbourg - Centre Hospitalier Universitaire [Strasbourg]
16 Clinique Victor Hugo [Le Mans]
17 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
18 Groupe Hospitalier Diaconesses Croix Saint-Simon
19 CHU Henri Mondor [Créteil]
20 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
21 U981 - Biomarqueurs prédictifs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse
22 Institut Jean Godinot [Reims]
23 SU - Sorbonne Université
24 Hôpital Cochin [AP-HP]
25 IRCM - U1194 Inserm - UM - Institut de Recherche en Cancérologie de Montpellier
26 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes
27 CHU Pitié-Salpêtrière [AP-HP]
28 CHD Vendée - Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon
29 Institut Sainte Catherine [Avignon]
30 IMRB - Institut Mondor de Recherche Biomédicale
31 CIC Rouen - Centre d'Investigation Clinique [CHU Rouen]

Background: Cisplatin-based combination chemotherapy before surgery is the standard of care for muscle-invasive bladder cancer. However, the optimal chemotherapy modalities have not been precisely defined to date.Patients and methods: In the VESPER trial, patients received after randomization either gemcitabine and cisplatin (GC, 4 cycles) or methotrexate, vinblastine, doxorubicin and cisplatin (dose dense [dd]-MVAC, 6 cycles). Creatinine clearance (CrCl) was calculated before each cycle according to the Cockroft and Gault formula. Definition criteria for local control after neoadjuvant chemotherapy included pathological complete response (ypT0N0), pathological downstaging (

Keywords: Cisplatin-based chemotherapy; Neoadjuvant treatment; Pathological complete response; Pathological downstaging; Perioperative chemotherapy

Domains: Cancer; Urology and Nephrology

Stéphane Culine, Valentin Harter, Gwenaelle Gravis, Aude Fléchon, Christine Chevreau, et al.. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Clinical Genitourinary Cancer, 2021, 19 (6), pp.554-562. ⟨10.1016/j.clgc.2021.08.005⟩. ⟨hal-03625944⟩